Rare disease patients face a number of unique challenges and complexities of their conditions, Often, this means that their families and advocates are more engaged with the scientific and research community in comparison to some other disease and patient focus groups. By collaborating with rare disease patients, their families and various stakeholders involved on the design, positioning and subsequent enrollment of clinical trials, studies can be completed faster and more efficiently. PRA Health Sciences' Scott Schliebner (Vice President, Rare Diseases, Scientific Affairs) and Altair da Silva (Senior Manager, Patient Access and Recruitment Services) are joined by Neil Weisman (Executive Vice President and General Manager at Blue Chip Marketing) to discuss the patient voice and the importance of patient and caregiver insight.
HEALEY ALS Platform Trial Drives Innovation in ALS Clinical Research
Amyotrophic lateral sclerosis (ALS) is a lethal, relentlessly progressive neurodegenerative disease, and the most common adult-onset motor neuron…
RARE DISEASES NEWSLETTER Volume 5, January 2017
This quarterly publication will keep you up to date on PRA’s Rare Disease Team focus, achievements, and new initiatives.
Shortening the Path to Rare Disease Diagnosis with a Patient-Centric Approach
Many rare disease patients struggle for years before they know what their symptoms indicate, and even longer to find a meaningful treatment. Learn…